This summary was created by AI, based on 13 opinions in the last 12 months.
Moderna (MRNA-Q) is a company that made the first Covid vaccine and experienced a surge in sales, but is now facing losses. It is working on a drug pipeline and a personalized cancer vaccine, but the success timeline is uncertain. The stock has experienced significant fluctuations in recent months, but some experts believe in the company's technology and future prospects.
It's had a huge price surge recently and is now too pricey. Prefers Pfizer.
A staple, and that sector is starting to outperform the market. A value play. His target is around $200-ish, if it can break resistance around $140. If it fails, give it a few days, and then walk away if you have to.
They have special technology; this morning they announced a collaboration with AI. Shares have been declining and there are sellers everywhere. You have to wait until they invent the special vaccines en masse they promised.
Believes in the CEO and their technology. Buy below $100.
Down 44% in 2023. They made the first Covid vaccine and made a ton of sales, but they suffer losses now. It didn't pull off a cancer vaccine as some hoped for. But it's up 9% in the past week. Maybe there's hope.
Covid vaccine was its first commercial product, and it did well. That's trailing off. Investing in drug pipeline, and it's hard to determine when products might be approved and launched. Her preference is a more established company with a pipeline.
A good mix of consumer goods and healthcare, but the PE is extended. Prefers to buy Pfizer for its growth and lower PE. He might even roll the dice with Moderna. Or buy the IBB, biotech ETF.
Down 26% in the last 23 months. It's suffering a post-Covid hangover and the company is better than this.
Is down 22% in the last 3 months. But he would but it. They're out of fashion, sure, and it's considered a Covid name, but their science is very good. A personalized cancer vaccine is possible.
They have developed a vaccine template that will benefit them going forward. Do not sell, but add more.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
They're holding an investor event on Monday. They delivered an early Covid vaccine, but shares have fallen since then. A smart CEO. They're working on a personalized cancer medication.
Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q
In the last year, 9 stock analysts published opinions about MRNA-Q. 5 analysts recommended to BUY the stock. 4 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Moderna.
Moderna was recommended as a Top Pick by on . Read the latest stock experts ratings for Moderna.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
9 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.
On 2024-07-26, Moderna (MRNA-Q) stock closed at a price of $122.17.
Moderna rallied 29% in May after a good report and news on developing a bird flu vaccine to fight that epidemic. Another boost came when the government approved their RSV vaccine. But Moderna is expected to lose money in the foreseeable future. Instead, look at biopharma.